Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,768.00
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.86
(
7.16%
)
Bitcoin
71,363.73
(
-3.49%
)
News Focus
News Focus
Post# of 257255
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

10nisman

Send PM Follow Ignore
Followers 24
Posts 2537
Boards Moderated 0
Alias Born 10/26/2003

10nisman

Re: biomaven0 post# 100115

Thursday, 07/29/2010 1:45:56 PM

Thursday, July 29, 2010 1:45:56 PM

Post# of 257255
<< That's at least arguable. It's not simply the market share and pricing pressure if Teva gets approved too, it's the changed profit split with Novartis that is the driver in that scenario. >>

Understood. Under my model, MNTA is worth approximately $22 at the lower profit split (not factoring in non-Lovenox programs).

10nis
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now